BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) represents a devastating form of stroke for which there is no effective treatment. This preclinical study was designed to evaluate dimethyl fumarate (DMF), a substance recently approved for the treatment of multiple sclerosis, as therapy for ICH. We hypothesized that DMF through activating the master regulator of cellular self-defense responses, transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), would act as effective treatment for ICH-mediated damage. METHODS: Male rats and mice, including Nrf2 knockouts, were subjected to intracerebral injection of blood (to mimic ICH) and then treated with DMF. Neurological deficit, brain edema, gene induction profile and hematoma resolution were evaluated. Phagocytic functions of primary microglia in culture were used to study hematoma resolution. RESULTS: Treatment with DMF induced Nrf2-target genes, improved hematoma resolution, reduced brain edema, and ultimately enhanced neurological recovery in rats and wild-type, but not Nrf2 knockout, mice. Most importantly, the treatment of ICH with DMF showed a 24 h window of therapeutic opportunity. CONCLUSIONS: A clinically relevant dose of DMF demonstrates potent therapeutic efficacy and impressive 24 h therapeutic window of opportunity. This study merits further evaluation of this compound as potential treatment for ICH in humans.
BACKGROUND AND PURPOSE:Intracerebral hemorrhage (ICH) represents a devastating form of stroke for which there is no effective treatment. This preclinical study was designed to evaluate dimethyl fumarate (DMF), a substance recently approved for the treatment of multiple sclerosis, as therapy for ICH. We hypothesized that DMF through activating the master regulator of cellular self-defense responses, transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), would act as effective treatment for ICH-mediated damage. METHODS: Male rats and mice, including Nrf2 knockouts, were subjected to intracerebral injection of blood (to mimic ICH) and then treated with DMF. Neurological deficit, brain edema, gene induction profile and hematoma resolution were evaluated. Phagocytic functions of primary microglia in culture were used to study hematoma resolution. RESULTS: Treatment with DMF induced Nrf2-target genes, improved hematoma resolution, reduced brain edema, and ultimately enhanced neurological recovery in rats and wild-type, but not Nrf2 knockout, mice. Most importantly, the treatment of ICH with DMF showed a 24 h window of therapeutic opportunity. CONCLUSIONS: A clinically relevant dose of DMF demonstrates potent therapeutic efficacy and impressive 24 h therapeutic window of opportunity. This study merits further evaluation of this compound as potential treatment for ICH in humans.
Authors: Ralf A Linker; De-Hyung Lee; Sarah Ryan; Anne M van Dam; Rebecca Conrad; Pradeep Bista; Weike Zeng; Xiaoping Hronowsky; Alex Buko; Sowmya Chollate; Gisa Ellrichmann; Wolfgang Brück; Kate Dawson; Susan Goelz; Stefan Wiese; Robert H Scannevin; Matvey Lukashev; Ralf Gold Journal: Brain Date: 2011-03 Impact factor: 13.501
Authors: Xiurong Zhao; Roger Strong; Jie Zhang; Guanghua Sun; Joe Z Tsien; Zhenzhong Cui; James C Grotta; Jaroslaw Aronowski Journal: J Neurosci Date: 2009-05-13 Impact factor: 6.167
Authors: Crissey L Pascale; Alejandra N Martinez; Christopher Carr; David M Sawyer; Marcelo Ribeiro-Alves; Mimi Chen; Devon B O'Donnell; Jessie J Guidry; Peter S Amenta; Aaron S Dumont Journal: J Cereb Blood Flow Metab Date: 2019-06-20 Impact factor: 6.200
Authors: Lei Liu; Mary K Vollmer; Abdullah S Ahmad; Victoria M Fernandez; Hocheol Kim; Sylvain Doré Journal: Free Radic Biol Med Date: 2018-11-17 Impact factor: 7.376
Authors: Lei Liu; Mary K Vollmer; Marie G Kelly; Victoria M Fernandez; Tyler G Fernandez; Hocheol Kim; Sylvain Doré Journal: Mol Neurobiol Date: 2019-09-07 Impact factor: 5.590